Aelis Farma
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
AELIS | PA
Overview
Corporate Details
- ISIN(s):
- FR0014007ZB4
- LEI:
- 8945008D5R6WV7EXRN47
- Country:
- France
- Address:
- 1 RUE LAFAURIE DE MONBADON, 33000 BORDEAUX
- Website:
- https://www.aelisfarma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and central nervous system (CNS) disorders. The company is pioneering a new class of drugs known as Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary technology represents a unique mechanism of action designed to treat brain pathologies by selectively blocking the hyperactivity of the CB1 receptor without interfering with its normal physiological functions. This approach aims to provide safer and more effective therapies for conditions with high unmet medical needs. The company's lead drug candidates include AEF0117 for cannabis-related disorders and AEF0217 for cognitive deficits, including those associated with Down syndrome.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-24 18:39 |
Share Issue/Capital Change
Acquisition ou cession des actions de l'émetteur / Modalités de mise à disposit…
|
French | 274.1 KB | ||
| 2025-06-24 18:39 |
Transaction in Own Shares
Acquisition or disposal of the issuer's own shares / Terms of availability of t…
|
English | 269.1 KB | ||
| 2025-05-27 18:00 |
Post-Annual General Meeting Information
Inside Information / Other news releases
|
English | 246.2 KB | ||
| 2025-05-27 18:00 |
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 250.5 KB | ||
| 2025-05-06 18:00 |
Pre-Annual General Meeting Information
Terms of availability of the preparatory documents for the GM
|
English | 269.8 KB | ||
| 2025-05-06 18:00 |
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | 255.0 KB | ||
| 2025-04-29 18:00 |
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 243.9 KB | ||
| 2025-04-29 18:00 |
Registration Form
Annual financial and audit reports / Terms of availability of the annual financ…
|
English | 260.7 KB | ||
| 2025-04-28 15:28 |
Annual Report (ESEF)
DEU 2024
|
French | 22.6 MB | ||
| 2025-04-01 18:26 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 375.3 KB | ||
| 2025-04-01 18:26 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 463.0 KB | ||
| 2025-03-26 18:00 |
Earnings Release
Inside Information / Other news releases
|
English | 339.9 KB | ||
| 2025-03-26 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 432.0 KB | ||
| 2025-03-24 10:31 |
Major Shareholding Notification
Franchissement de seuils
|
French | 205.4 KB | ||
| 2025-01-08 18:00 |
Regulatory News Service
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 373.0 KB |
Automate Your Workflow. Get a real-time feed of all Aelis Farma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Aelis Farma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
